The Parkinson’s disease treatment market value across the eight major countries of the US, France, Germany, Italy, Spain, the UK, Japan, and Brazil will reach $4.7 billion by 2022, driven primarily by an aging population and increasing disease prevalence.
Reportstack’s latest report "PharmaPoint: Parkinsons Disease-Global Drug Forecast and Market Analysis to 2022-Event Driven update" states that most late-stage pipeline agents are set to meet the needs of advanced Parkinson’s disease patients, with three drugs expected to launch by 2022, namely CVT-301, opicapone, and tozadenant.
In a strong first quarter for Parkinson’s disease treatment, Impax’s Rytary was approved by the US Food and Drug Administration (FDA) in January 2015, while Newron’s Xadago was approved in Europe in February and accepted for a New Drug Application by the FDA in March. Additionally, AbbVie’s Duopa, which has been available for over 10 years in Europe, also gained US approval in Q1 2015.
The most promising products are Xadago and Rytary for early and advanced patients, and Acorda’s CVT-301 for advanced patients.
“Xadago will be a strong market competitor for early and advanced-stage Parkinson’s disease patients, prescribed ahead of Teva/Lundbeck’s Azilect (rasagiline), due to its additional activity as a glutamate-release inhibitor.
“Also making an impact will be Rytary, a slow-release formulation of levodopa that has shown good efficacy and improvements in quality of life during clinical trials. It was predicted that global sales for Xadago and Rytary will reach $409.6 million and $202.2 million, respectively, by 2022.”
The analyst adds that CVT-301 is a novel reformulation of levodopa and the first inhaled drug for Parkinson’s disease. It is expected to be the first widely-used emergency therapy to fulfill a key unmet need in wearing-off, and is forecast to garner strong sales of $458.6 million in 2022.
While GlobalData does not expect a disease-modifying agent to be introduced during the forecast period, the entry of any such product would be the most significant advancement in Parkinson’s disease therapeutics since the development of levodopa in the 1960s.
“Many early-stage clinical and preclinical programs are in progress towards reaching this goal, such as AstraZeneca’s Phase II drug, AZD-3241, a myeloperoxidase inhibitor that aims to reduce neuroinflammation.
“The Parkinson’s disease treatment market is very dynamic, with abundant opportunities for partnerships in both the early and late stages of clinical development,”